These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31729149)

  • 21. Statistical and practical considerations in designing of immuno-oncology trials.
    Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
    J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sample size computation for two-sample noninferiority log-rank test.
    Jung SH; Kang SJ; McCall LM; Blumenstein B
    J Biopharm Stat; 2005; 15(6):969-79. PubMed ID: 16279355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
    Zhang F; Miyaoka E; Huang F; Tanaka Y
    J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
    Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
    Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
    Yu C; Huang X; Nian H; He P
    Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-arm Phase II cancer survival trial designs.
    Wu J
    J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
    Wu J; Zhu L; Li Y
    J Biopharm Stat; 2023 Dec; ():1-14. PubMed ID: 38146192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
    Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
    J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
    Wang J
    J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect.
    Li B; Zhang J; Yang W; Su L; Yan F
    Pharm Stat; 2024; 23(1):107-133. PubMed ID: 37859531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive promising zone design for cancer immunotherapy with heterogeneous delayed treatment effect.
    Li B; Yan F; Jiang D
    J Biopharm Stat; 2024 Apr; ():1-20. PubMed ID: 38615361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
    Hamasaki T; Evans SR; Asakura K
    J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A sample size formula for the supremum log-rank statistic.
    Eng KH; Kosorok MR
    Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size re-estimation for adaptive sequential design in clinical trials.
    Gao P; Ware JH; Mehta C
    J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies.
    Hasegawa T
    Pharm Stat; 2014; 13(2):128-35. PubMed ID: 24497461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
    Wu J
    J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.